Imaging brain changes in PTSD and Alcohol Use Disorder
Official title: Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
Run by Yale University · NCT06371404 · Data updated 2026-11-12
This study is testing if brain imaging can help us understand how a specific marker is related to PTSD and Alcohol Use Disorder in people who have these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Yale University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (New Haven, Connecticut) |
| Status | Recruiting |
| Started | June 5, 2024 |
| Main results expected | June 1, 2030 |
| Study ends | June 1, 2031 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT06371404 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 70 with a current diagnosis of PTSD or AUD, or those with both conditions.
✕Probably not a fit
Patients without a diagnosis of PTSD or AUD, or those who do not meet the study's health criteria, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to utilize Positron Emission Tomography (PET) imaging with the radiotracer [18F]Bavarostat to investigate the expression of the epigenetic marker Histone Deacetylase 6 (HDAC6) in individuals with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or both. A total of 150 subjects will undergo MRI and PET imaging, along with behavioral and cognitive assessments, to explore the relationship between HDAC6 levels and clinical variables. The study will compare HDAC6 expression in affected individuals against healthy control groups to better understand the neurobiological underpinnings of these disorders.
Why it matters
Potential benefit: If successful, this study could lead to targeted treatment developments for PTSD and Alcohol Use Disorder based on biological markers.
How similar studies have gone: While there have been numerous preclinical studies on stress and addiction, this approach using HDAC6 imaging in humans is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing and able to give voluntary written informed consent 2. Is able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the research staff 3. Men or women, aged 18 to 70, at screening 4. In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry, hematology, and serology tests 5. Participants with PTSD will have a current diagnosis of PTSD according to DSM-5 criteria (CAPS-5 ascertained diagnosis, confirmed by the Principal Investigators. TC subjects must have a DSM-5 criteria traumatic event with no PTSD diagnosis 6. Participants with AUD will have a current diagnosis of AUD according to DSM-5 criteria (i.e., SCID-5 ascertained diagnosis, confirmed by the Principal Investigators); 7. Participants with AUD will meet the following drinking criteria: males will drink \> 14 drinks per week and exceed 4 drinks per day at least twice per week; females will drink \> 7 drinks per week and exceed 3 drinks per day at least twice per week. They must meet drinking criteria during a consecutive 30-day period within the 90 days prior to intake. 8. Healthy subjects will have no current or past diagnosis of AUD or other significant substance use disorder. They will drink less than 5 alcoholic drinks per week with no heavy drinking days (i.e., \>4 drinks/day for men; \>3 drinks/day for women) in the last 30 days; Exclusion Criteria: 1. Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology that would impact the integrity of the data (note that elevated liver enzymes for individuals with AUD will not be exclusionary) 2. Past or current neurological disorder or disorders affecting the brain including but not limited to multiple sclerosis, history of stroke, brain tumors, traumatic brain injury with loss of consciousness, seizure disorder; 3. Current significant psychiatric disorder including severe substance use disorder (other than alcohol or tobacco use disorders\*), and past or current psychotic symptoms, 4. Regular use in the past 6 months of any prescription, psychoactive or herbal medications (e.g., antidepressants, antipsychotics, anxiolytics) that would impact the integrity of the data (e.g., naltrexone); No subject will be asked to stop taking medication to participate in the study; 5. Pregnancy or lactation 6. Blood donation within eight weeks of the start of the study. 7. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto). 8. Unable to safely discontinue or hold aspirin and other NSAID use 9. MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects/fragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist). 10. Participation in other research studies involving inonizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for healthy volunteers. 11. Subject who has current, past, or anticipated exposure to radiation in the work place within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits. 12. Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol. 13. History of complicated alcohol withdrawal including history of delirium tremens; seizure, hospitalization for withdrawal. 14. Alcohol intoxication at time of screening. 15. A CIWA score ≥8 at intake or on scan day. 16. Subjects who are, in the opinion of the study physician, unable to safely abstain from alcohol overnight prior to their study visits.
Where it's running
-
Yale University
New Haven, Connecticut, United States Recruiting
Study contacts
- Study coordinator: Kelly Cosgrove
- Email: kelly.cosgrove@yale.edu
- Phone: 2037376969
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MDMA-assisted therapy for veterans with PTSD and alcohol use disorder
This study tests MDMA-assisted therapy versus a low-dose MDMA placebo with psychotherapy to see if it helps veterans who have PTSD and problem drinking.
-
Using topiramate to treat alcohol use disorder and PTSD together
This study is testing if the medication topiramate can help people who have both alcohol use disorder and PTSD feel better.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Anger, Social Thinking, and PTSD in French Veterans
This study tests whether PTSD in former French military personnel is linked to higher anger through changes in social thinking abilities.
-
Thiamine to reduce brain injury in adults with alcohol use disorder
This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.
-
TSND-201 treatment for PTSD in adults
This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.